Brief: Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results And Provides Business Update On Key 2023 Objectives

Aquestive Therapeutics

07/03/2023 21:17

March 7 (Reuters) - Aquestive Therapeutics Inc  AQST.O :
    * AQUESTIVE THERAPEUTICS REPORTS FOURTH QUARTER & FULL YEAR
2022
FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ON KEY 2023
OBJECTIVES
    * Q4 REVENUE FELL 4 PERCENT TO $10.7 MILLION
    * PIVOTAL STUDY FOR AQST-109 (EPINEPHRINE SUBLINGUAL FILM)
ON
TRACK TO START IN Q3 2023
    * AQUESTIVE THERAPEUTICS-FINANCIAL TURNAROUND ACTIONS ON
TRACK
INCLUDING 18% REDUCTION OF OUTSTANDING DEBT, RECEIPT OF $20
MILLION OF NON-DILUTIVE CAPITAL IN Q1 2023
    * SEES 2023 TOTAL REVENUE $37 MILLION TO $41 MILLION
    * SEES 2023 NON-GAAP ADJUSTED EBITDA LOSS $31 MILLION TO $36
MILLION
    * QTRLY LOSS PER SHARE $0.23
    * Q4 EARNINGS PER SHARE VIEW $-0.23, REVENUE VIEW $10.4
MILLION --
REFINITIV IBES DATA
    * FY2023 REVENUE VIEW $37.8 MILLION -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX4slRVx 
Further company coverage:  AQST.O 

 ((Reuters.Briefs@thomsonreuters.com;;))